Search Results - "DE MURO, Marianna"

Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program by Rambaldi, Alessandro, Iurlo, Alessandra, Vannucchi, Alessandro M., Martino, Bruno, Guarini, Attilio, Ruggeri, Marco, von Bubnoff, Nikolas, De Muro, Marianna, McMullin, Mary Frances, Luciani, Stefania, Martinelli, Vincenzo, Nogai, Axel, Rosti, Vittorio, Ricco, Alessandra, Bettica, Paolo, Manzoni, Sara, Di Tollo, Silvia

“…Polycythemia vera (PV) is a BCR-ABL1 -negative myeloproliferative neoplasm (MPN) characterized by excessive proliferation of erythroid, myeloid, and…”
Get full text

Impact on mental health, disease management, and socioeconomic modifications in hematological patients during the COVID-19 pandemic in Italy by De Muro, Marianna, Janssen, Annelot Julia, Amadori, Sergio, de Fabritiis, Paolo, Sabatino, Dante, Niscola, Pasquale, Torti, Lorenza, Trawinska, Malgorzata Monika, Tesei, Cristiano, Bombaci, Felice, Tarricone, Mario, Bocchia, Monica, Fava, Carmen, Galimberti, Sara, Iurlo, Alessandra, Luciano, Luigia, Abruzzese, Elisabetta

“…Background: Hematological patients are a highly vulnerable population with an increased risk of developing severe COVID-19 symptoms due to their…”
Get full text

Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study by Rambaldi, Alessandro, Iurlo, Alessandra, Vannucchi, Alessandro M., Noble, Richard, von Bubnoff, Nikolas, Guarini, Attilio, Martino, Bruno, Pezzutto, Antonio, Carli, Giuseppe, De Muro, Marianna, Luciani, Stefania, McMullin, Mary Frances, Cambier, Nathalie, Marolleau, Jean-Pierre, Mesa, Ruben A., Tibes, Raoul, Pancrazzi, Alessandro, Gesullo, Francesca, Bettica, Paolo, Manzoni, Sara, Di Tollo, Silvia

Get full text

Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients by Andriani, Alessandro, Latagliata, Roberto, Anaclerico, Barbara, Spadea, Antonio, Rago, Angela, Di Veroli, Ambra, Spirito, Francesca, Porrini, Raffaele, De Muro, Marianna, Crescenzi Leonetti, Sabrina, Villivà, Nicoletta, De Gregoris, Cinzia, Montefusco, Enrico, Polverelli, Nicola, Santoro, Cristina, Breccia, Massimo, Cimino, Giuseppe, Majolino, Ignazio, Mazzucconi, Maria Gabriella, Vianelli, Nicola, Alimena, Giuliana, Montanaro, Marco, Palandri, Francesca

“…Spleen enlargement, present in 10–20% of Essential Thrombocythemia (ET) patients at diagnosis, is a feature clinically easy to assess, confirmable by…”
Get full text

Thrombosis and survival in essential thrombocythemia: A regional study of 1,144 patients by Montanaro, Marco, Latagliata, Roberto, Cedrone, Michele, Spadea, Antonio, Rago, Angela, Giandomenico, Jonny, Spirito, Francesca, Porrini, Raffaele, Muro, Marianna, Leonetti, Sabrina Crescenzi, Villivà, Nicoletta, Gregoris, Cinzia, Breccia, Massimo, Montefusco, Enrico, Santoro, Cristina, Cimino, Giuseppe, Majolino, Ignazio, Mazzucconi, Maria Gabriella, Alimena, Giuliana, Andriani, Alesssandro

“…To identify prognostic factors affecting thrombosis‐free survival (TFS) and overall survival (OS), we report the experience of a Regional cooperative group in…”
Get full text

Imatinib resistance: diagnostic and therapeutic choices by De Muro, Marianna, Olimpieri, Odoardo Maria, Greco, Rosa, Altomare, Lidia

“…We report a case of a 42-year-old woman with t(9;22) positive chronic myeloid leukemia (CML) who developed a sub-optimal response to therapy with imatinib…”
Get full text

Proposal and Validation of Prognostic Scoring Systems for IgG and IgA Monoclonal Gammopathies of Undetermined Significance by ROSSI, Francesca, PETRUCCI, Mariateresa, MUSTO, Pellegrino, BACIGALUPO, Andrea, GAIDANO, Gianluca, AVVISATI, Giuseppe, GOLDANIGA, Maria, DEPAOLI, Lorenzo, BALDINI, Luca, GUFFANTI, Andrea, MARCHESELLI, Luigi, ROSSI, Davide, CALLEA, Vincenzo, VINCENZO, Federico, DE MURO, Marianna, BARALDI, Alessandra, VILLANI, Oreste

“…Purpose: The presenting clinico-hematologic features of 1,283 patients with IgG and IgA monoclonal gammopathies of undetermined significance (MGUS) were…”
Get full text

Impact on Mental Health, Disease Management and Socioeconomic Modifications in Hematological Patients during COVID-19 Pandemia in Italy by De Muro, Marianna, Amadori, Sergio, Ardu, Nicolina Rita, Cerchiara, Elisabetta, De Fabritiis, Paolo, Niscola, Pasquale, Dante, Sabatino, Schittone, Valentina, Tesei, Cristiano, Trawinska, Malgorzata Monika, Abruzzese, Elisabetta

“…The SARS-CoV-2 (COVID-19) outbreak is upending current life and generating much anxiety and uncertainty. The effects of home confinement, social isolation,…”
Get full text

Sequential occurrence of chronic myeloproliferative and lymphoproliferative neoplasms: a collaborative retrospective study by pH-negative MPN latial group by Breccia, Massimo, Petriccione, Luca, Tatarelli, Caterina, De Muro, Marianna, Trawinska, Malgorzata Monica, Santopietro, Michelina, Spadea, Antonio, Di Veroli, Ambra, Scalzulli, Emilia, Paciaroni, Katia, Tafuri, Agostino, Latagliata, Roberto, Andriani, Alessandro, Di Napoli, Arianna

Get full text

Characterization of three novel pathogenic SLC40A1 mutations and genotype/phenotype correlations in 7 Italian families with type 4 hereditary hemochromatosis by Majore, Silvia, Bonaccorsi di Patti, Maria Carmela, Valiante, Michele, Polticelli, Fabio, Cortese, Andrea, Di Bartolomeo, Sabrina, De Bernardo, Carmelilia, De Muro, Marianna, Faienza, Fiorella, Radio, Francesca Clementina, Grammatico, Paola, Musci, Giovanni

“…Mutations of SLC40A1 encoding ferroportin (Fpn), the unique cellular iron exporter, severely affect iron homeostasis causing type 4 hereditary hemochromatosis,…”
Get full text

Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase by Latagliata, Roberto, Montagna, Chiara, Porrini, Raffaele, Di Veroli, Ambra, Leonetti, Sabrina Crescenzi, Niscola, Pasquale, Ciccone, Fabrizio, Spadea, Antonio, Breccia, Massimo, Maurillo, Luca, Rago, Angela, Spirito, Francesca, Cedrone, Michele, De Muro, Marianna, Montanaro, Marco, Andriani, Alessandro, Bagnato, Antonino, Montefusco, Enrico, Alimena, Giuliana

“…At present, very few data are available on deferasirox (DFX) in the treatment of patients with Philadelphia‐negative myeloproliferative neoplasms in fibrotic…”
Get full text

Deferasirox in the Treatment of Iron Overload during Myeloproliferative Neoplasms (MPN) by Porrini, Raffaele, Campagna, Alessia, De Muro, Marianna, Trawinska, Malgorzata, Di Veroli, Ambra, Leonetti Crescenzi, Sabrina, Petruccione, Luca, Romano, Atelda, D'Addosio, Ada, Rago, Angela, Montanaro, Marco, Andriani, Alessandro, Niscola, Pasquale, Montefusco, Enrico, Breccia, Massimo, Alimena, Giuliana, Latagliata, Roberto, Tafuri, Agostino

“…Background Deferasirox (DFX) is an oral iron chelator widely employed in the treatment of iron overload during thalassemic syndromes and myelodysplastic…”
Get full text

High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia by Latagliata, Roberto, Montanaro, Marco, Cedrone, Michele, Di Veroli, Ambra, Spirito, Francesca, Santoro, Cristina, Crescenzi, Sabrina Leonetti, Porrini, Raffaele, Di Giandomenico, Jonny, Villivà, Nicoletta, Spadea, Antonio, Rago, Angela, De Gregoris, Cinzia, Romano, Atelda, Anaclerico, Barbara, De Muro, Marianna, Felici, Stefano, Breccia, Massimo, Montefusco, Enrico, Bagnato, Antonino, Cimino, Giuseppe, Majolino, Ignazio, Mazzucconi, Maria Gabriella, Alimena, Giuliana, Andriani, Alessandro

“…Abstract To assess the role of platelet (PLT) count for thrombotic complications in Essential Thrombocythemia (ET), 1201 patients followed in 11 Hematological…”
Get full text

Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera: A retrospective analysis of 623 PTS With long follow-up by Di Veroli, Ambra, Buccisano, Francesco, Andriani, Alessandro, Montanaro, Marco, Latagliata, Roberto, Santoro, Cristina, Breccia, Massimo, Spirito, Francesca, Cedrone, Michele, Anaclerico, Barbara, Leonetti Crescenzi, Sabrina, Porrini, Raffaele, De Muro, Marianna, Avvisati, Giuseppe, Tafuri, Agostino, Cimino, Giuseppe, Spadea, Antonio

Get full text

A Two-Part Study of Givinostat in Patients with Polycythemia Vera: The Maximum Tolerated Dose Selection and the Proof of Concept Final Results by Rambaldi, Alessandro, Iurlo, Alessandra, Vannucchi, Alessandro M., Noble, Richard, von Bubnoff, Nikolas, Guarini, Attilio, Hellmann, Andrzej, Martino, Bruno, Pezzutto, Antonio, Carli, Giuseppe, De Muro, Marianna, Di Bartolomeo, Paolo, McMullin, Mary Frances Frances, Cambier, Nathalie, Marolleau, Jean-Pierre, Mesa, Ruben A, Tibes, Raoul, Bettica, Paolo, Manzoni, Sara, DI Tollo, Silvia

“…Background and purpose of the study: Several reports have documented that histone deacetylase inhibitors induce neoplastic cells to undergo growth arrest,…”
Get full text

A Long-Term Safety and Efficacy Study of Givinostat in Patients with Polycythemia Vera: The First 4 Years of Treatment by Finazzi, Guido, Iurlo, Alessandra, Martino, Bruno, Carli, Giuseppe, Guarini, Attilio, Noble, Richard, Vannucchi, Alessandro M., von Bubnoff, Nikolas, De Muro, Marianna, Di Bartolomeo, Paolo, McMullin, Mary Frances, Martinelli, Vincenzo, Pezzutto, Antonio, Rosti, Vittorio, Specchia, Giorgina, Bettica, Paolo, Manzoni, Sara, DI Tollo, Silvia, Rambaldi, Alessandro

“…Background and purpose of the study: Chronic myeloproliferative neoplasms (cMPN) are clonal diseases resulting from the transformation of a multi-potent…”
Get full text

Primary Myelofibrosis in Younger Patients: A Retrospective Analysis of the Gruppo Laziale MPN Ph-Negative by Breccia, Massimo, Di Veroli, Ambra, De Muro, Marianna, Trawinska, Malgorzata Monika, Crescenzi Leonetti, Sabrina, Cedrone, Michele, Petriccione, Luca, Romano, Atelda, D'Addosio, Ada, Molica, Matteo, Centra, Antonia, Porrini, Raffaele, Felici, Stefano, Maurillo, Luca, Montanaro, Marco, Andriani, Alessandro, Niscola, Pasquale, Foa, Robin, Latagliata, Roberto

“…Primary myelofibrosis (PMF) is a rare disorder commonly diagnosed in the 6th-7th decade of life. In this retrospective study, we analyzed the clinical features…”
Get full text

Incidence of Early Adverse Events in Primary Myelofibrosis (PMI). a Prospective Analysis from the Gruppo Laziale of Ph-Negative MPN by Di Veroli, Ambra, Rossi, Elena, Breccia, Massimo, De Muro, Marianna, Villivà, Nicoletta, Trawinska, Malgorzata Monika, Crescenzi Leonetti, Sabrina, Montanaro, Guido, Romano, Atelda, Petriccione, Luca, D'Addosio, Ada, Centra, Antonia, Rauco, Annamaria, Anaclerico, Barbara, Abruzzese, Elisabetta, Maurillo, Luca, Carmosino, Ida, Montanaro, Marco, Andriani, Alessandro, De Stefano, Valerio, Foa, Robin, Latagliata, Roberto

“…Background. Adverse events are relatively more common in the follow-up of primary myelofibrosis (PMI) than in other Ph- myeloproliferative neoplasms, with…”
Get full text

Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter? by Di Veroli, Ambra, Campagna, Alessia, De Muro, Marianna, Maurillo, Luca, Trawinska, Malgorzata Monika, LeonettiCrescenzi, Sabrina, Petriccione, Luca, Romano, Atelda, D’Addosio, Ada, Cenfra, Antonia, Montanaro, Marco, Felici, Stefano, Andriani, Alessandro, Carmosino, Ida, Niscola, Pasquale, Montefusco, Enrico, Breccia, Massimo, Latagliata, Roberto

“…•Iron overload is a major concern in Ph-negative myeloproliferative neoplasms in fibrotic phase.•The clinical use of DFX and its benefit are not consolidated…”
Get full text

Symptomatic Mucocutaneous Toxicity of Hydroxyurea in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: The Mister Hyde Face of a Safe Drug by LATAGLIATA, Roberto, SPADEA, Antonio, RAGO, Angela, AVVISATI, Giuseppe, ALIMENA, Giuliana, MONTANARO, Marco, ANDRIANI, Alessandro, CEDRONE, Michele, DI GIANDOMENICO, Jonny, DE MURO, Marianna, VILLIVA, Nicoletta, BRECCIA, Massimo, ANACLERICO, Barbara, PORRINI, Raffaele, SPIRITO, Francesca

“…The current study was conducted to evaluate severe mucocutaneous toxicity during treatment with hydroxyurea (HU) in a large cohort of patients with…”
Get full text